NEOGEN CORP Form 8-K July 27, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 21, 2016

NEOGEN CORPORATION

(Exact name of registrant as specified in its charter)

MICHIGAN (State or other jurisdiction of incorporation) 0-17988 (Commission File Number) 38-2367843 (IRS Employer Identification No.)

620 Lesher Place Lansing, Michigan (Address of principal executive offices)

48912 (Zip Code)

Edgar Filing: NEOGEN CORP - Form 8-K

Registrant s telephone number, including area code 517-372-9200

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 21, 2016, Dr. Clayton Yeutter informed the Board of Directors of the Company that he would not stand for re-election as a member of the Board when his current term expires in October 2016.

Dr. Yeutter, 86, has been a member of the Board of Directors since 2007 and is not standing for re-election for personal reasons. The Company advises that the Board of Directors expects to present a nominee to succeed Dr. Yeutter on the Board; this nominee is expected to be included in the Company s proxy statement, which will be mailed to shareholders at the end of August 2016.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOGEN CORPORATION (Registrant)

Date: July 27, 2016

/s/ Steven J. Quinlan Steven J. Quinlan Vice President & CFO